Instrumentation Laboratory Acquires CA CASYSO AG, Including TEM® subsidiaries and ROTEM® Testing Systems

26. September 2016

TS102298Instrumentation Laboratory (IL) acquired CA Casyso AG (Basel, Switzerland) and its Tem subsidiaries (Tem), a global leader in in vitro diagnostic (IVD) testing for Patient Blood Management (PBM) with their flagship ROTEM testing systems.

Tem is a global leader in in-vitro-diagnostic (IVD) testing for Patient Blood Management (PBM) with their flagship ROTEM testing systems. With a direct sales force in seven markets, including the US, Tem has consistently achieved above-market growth in the PBM market. In hospital trauma and surgical patients with clinically significant bleeding, ROTEM whole blood analyzers provide a rapid differential diagnosis of coagulopathies. This supports targeted transfusion and coagulation factor concentrate therapy and, as a result, is key to PBM programs. PBM is a multi-disciplinary, evidence based medical concept, optimizing a patient’s own blood volume, minimizing blood loss and thereby significantly reducing or avoiding blood transfusion.

ROTEM testing systems leverage technology known as rotational thromboelastometry. Rapidly detecting coagulopathies associated with perioperative bleeding, allows treatment with targeted therapy, thereby minimizing or preventing massive bleeding and hemorrhagic shock. ROTEM systems provide reliable results for differential diagnosis and treatment within 10-15 minutes, versus 45-60 minutes for traditional laboratory testing. ROTEM systems include ROTEM Delta and ROTEM Sigma for whole blood IVD testing in satellite and central laboratories.

Instrumentation Laboratory, founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company’s product lines include Critical Care systems, Hemostasis systems and Information Management systems.

IL GEM® product offerings, part of the Critical Care line, include the GEM Premier™ 4000 analyzer with Intelligent Quality Management (iQM®), GEM Premier 3500 and GEMweb® Plus Custom Connectivity. The IL Hemostasis portfolio includes new ACL TOP Family 50 Series Hemostasis Testing Systems and the original ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers. IL also offers the ACL AcuStar®, ACL Elite®, and other Hemostasis analyzers, along with the comprehensive HemosIL® line of reagents.  IL is based in Bedford, Massachusetts.

“A passion for innovation, leading systems and extensive knowledge in PBM, make Tem a perfect complement to our focus, commitment, and leadership in Hemostasis and Critical Care IVD,” said Ramon Benet, CEO at IL. “IL and our global Werfen organizations are ideally positioned to maximize the potential of the ROTEM product line, which intersects our existing business and presents synergies in our core competencies and customer call points. Most importantly, ROTEM systems share the same ultimate benefit of all our products – to help customers reduce overall hospital costs, while improving patient care.”

Oaklins Switzerland advised the shareholders of Tem-Group in the entire sale process.